KALA News and Press, Kala Pharmaceuticals Inc. From 03/09/20

Kala Pharmaceuticals (NASDAQ: KALA ) is up  13%  premarket on light volume in reaction to its announcement that a Phase 3 clinical trial, STRIDE 3 , evaluating lead candidate KPI-121 in patients with dry eye disease. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks ...

– STRIDE 3 Met Both Prespecified Primary Efficacy Endpoints, Ocular Discomfort Severity in the Overall ITT Population and in ITT Patients with More Severe Baseline Discomfort – – STRIDE 3 Met Key Sign Endpoint of Conjunctival Hyperemia – – Data Enabl...

"Cauliflower is nothing but cabbage with a college education ." - Mark Twain Today, we revisit Kala Pharmaceuticals ( KALA ). This intriguing small-cap concern posted solid Q4 results last week. We highlight key aspects for its fourth-quarter earnings report, take a look at what is on h...

Kala Pharmaceuticals, Inc. (KALA) Q4 2019 Earnings Conference Call February 12, 2020 08:00 AM ET Company Participants Niranjan Kameswaran - Senior Vice President, Strategy Mary Reumuth - Chief Financial Officer Mark Iwicki - Chairman, President & Chief Executive Officer Kim...

Kala Pharmaceuticals ( KALA ) Q4 results : Revenues: $1.2M. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Kala Pharmaceuticals (NASDAQ: KALA ): Q4 GAAP EPS of -$0.63 misses by $0.03 . More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter of 2020 – – Achieved Full Year 2019 INVELTYS® Revenues of $6.1 Million – – Conference Call and Webcast Today at 8:00 a.m....

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report fourth quarter and full ...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this Read more ...

Kala Pharmaceuticals (NASDAQ: KALA ) has completed enrollment of ~900 patients in its STRIDE 3 (Short Term Relief In Dry Eye) Phase 3 clinical trial for KPI-121 0.25%, for the short-term treatment of dry eye disease. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news, ...